Posters

      Correlative Histopathology and Systems Biology Approach in Product Risk Assessment

      Schlage, W.; Ansari, S.; Xiang, Y.; Quadt-Humme, S.; Kogel, U.; Gebel, S.; Hengstermann, A.; Hoeng, J.; Peitsch, M.; Buettner, A.; Meurrens, K.
      Conference date
      Mar 7, 2011
      Conference name
      Society of Toxicology (SOT) 2011
      Link to more information
      Link to more information
      Topic
      Summary

      With a view to developing a systems biology-based product risk assessment approach, classical toxicology was combined with analysis of gene expression and protein abundance to investigate disease-relevant molecular perturbations at the sites of histopathological changes in an OECD 28-d rat inhalation study. Rats were exposed for 28 d to filtered air (SHAM), or to a low, medium, or high concentration of cigarette mainstream smoke (MS). Histopathology of respiratory tract sections revealed typical dose-dependent adaptive changes in the airway epithelia and inflammatory responses in the lung. For each rat, respiratory nasal epithelium (RNE) was dissected bilaterally and split for RNA and protein samples. Whole lung cryosections were used for protein samples; respiratory epithelium of the main bronchus and lung parenchyma were separated by laser capture microscopy for RNA samples. Systems profiles of gene expression (affymetrix microarrays) and principal component analysis (PCA) showed MS dose-dependent numbers of significantly up- or down-regulated genes in all 3 tissues. The differentially regulated genes were related mainly to the expected pathways, e.g., inflammation, oxidative and ER stress, etc. Correlating with histological changes, stress-related responses were more pronounced in RNE, while inflammatory responses were more pronounced in lung parenchyma. Reverse protein arrays (RPA) analysis generated systems response profiles for 46 (RNE) and 47 (lung) proteins / protein modifications. PCA showed clear separation of all MS groups from sham for RNE, and of the high MS group from sham for the lung. RNE from the medium and high MS groups differed significantly from sham in the abundance of proteins related to pathways, including the MAPK-stress signaling pathway. Responses were less pronounced in the lung. In conclusion, a correlative evaluation of classical histopathology with molecular patterns (gene expression and RPA) may facilitate a systems biology-based product risk assessment approach. 

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.